We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double digits.

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report)’s share price dropped 3.8% during trading on Friday . The stock traded as low as $10.81 and last traded at $10.78. Approximately 201,759 shares ...

Vir Biotechnology (NASDAQ:VIR – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a ...

Vir Biotechnology Inc (VIR) stock saw a modest uptick, ending the day at $11.2 which represents a slight increase of $0.67 or 6.36% from the prior close of $10.53. The stock opened at $10.48 and ...

Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.

Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) on January 13 and set a price target ...

These initial results provide clinical support for Vir Biotechnology’s in-licensed PRO-XTEN™ masking technology, which is designed to enable the selective activation of TCEs in the tumor ...

Vir Biotechnology Inc (VIR) stock saw a decline, ending the day at $12.1 which represents a decrease of $-0.38 or -3.04% from the prior close of $12.48. The stock opened at $12.69 and touched a low of ...

The average one-year price target for Vir Biotechnology (NasdaqGS:VIR) has been revised to 33.08 / share. This is an increase of 9.93% from the prior estimate of 30.09 dated January 16 ...

In a report released today, Gena Wang from Barclays assigned a Buy rating to Vir Biotechnology (VIR – Research Report), with a price target of ...

On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid ...